Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis-Reference-Cited by-同舟云学术

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis

Published:2016-09-22 Issue:12 Volume:128 Page:1609-1613
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pavlasova Gabriela¹²,Borsky Marek²,Seda Vaclav¹²,Cerna Katerina¹²,Osickova Jitka²,Doubek Michael²,Mayer Jiri²,Calogero Raffaele³,Trbusek Martin²,Pospisilova Sarka²,Davids Matthew S.⁴,Kipps Thomas J.⁵,Brown Jennifer R.⁴,Mraz Marek¹²

Affiliation:

1. Central European Institute of Technology, Masaryk University, Brno, Czech Republic;

2. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;

3. Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy;

4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and

5. Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA

Abstract

Key Points Microenvironmental interactions upregulate CD20 expression in CLL cells through the CXCR4/SDF-1 axis. Ibrutinib treatment causes downregulation of CD20 in CLL cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/12/1609/1396117/1609.pdf

Reference24 articles.

1. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

2. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.;Furman;N Engl J Med,2014

3. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.;de Rooij;Blood,2012

4. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.;Ponader;Blood,2012

5. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.;Seda;Eur J Haematol,2015

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. NF-kB affects migration of vascular smooth muscle cells after treatment with heparin and ibrutinib;Biochemistry and Biophysics Reports;2024-07

3. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia;Leukemia;2024-06-24

4. Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs;Leukemia;2024-06-14

5. Potential New Therapies “ROS-Based” in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis;Antioxidants;2024-04-17